1. Enliven Therapeutics will present at three key investor conferences in 2025. 2. The conferences focus on oncology innovation and global healthcare trends. 3. Management will share insights on their small molecule therapeutics development. 4. Webcasts will be available live and archived for 90 days. 5. Enliven aims to address unmet cancer treatment needs through precision oncology.
The participation in high-profile conferences can enhance visibility and investor confidence, similar to past biotech uplifts during major conferences.
Presenting at recognized events can attract more investments and partnerships, affecting stock price positively.
The immediate effect relates to investor engagement and market perception leading up to the events, potentially increasing ELVN's stock interest shortly.
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will present at the following investor conferences:
Format: Fireside Chat
Date: Tuesday, May 27, 2025
Time: 1:00 p.m. ET
Format: Fireside Chat
Date: Wednesday, June 4, 2025
Time: 4:20 p.m. ET
Format: Fireside Chat
Date: Tuesday, June 10, 2025
Time: 4:00 p.m. ET
The fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. Each webcast will be archived for a period of 90 days following the conclusion of the live event.
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.
SOURCE Enliven Therapeutics, Inc.